Future horizons in Alzheimer's disease research.

There are growing genetic, transcriptomic and proteomic data pointing to the complexity of Alzheimer's disease (AD) pathogenesis. Unbiased "omics" approaches are essential for the future development of effective AD research, which will need to be combined and personalized, given that multiple distinct pathways can drive AD pathology. It is essential to gain a better understanding of the AD pathogenesis subtype variety and to develop several distinct therapeutic approaches tailored to address this diversity, as well as the common presence of mixed pathologies. These nonmutually exclusive therapeutic approaches include the targeting of multiple toxic oligomeric species concurrently, targeting the apolipoprotein E/amyloid β interaction and the modulation of innate immunity, as well as more "out of the box" ideas such as targeting infectious agents that may play a role in AD.

• Publication year

  2019

• Venue

  Progress in Molecular Biology and Translational Science

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/BS.PMBTS.2019.08.001PMID 31699317
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer’s disease and not in other tauopathies

  2019cited by this paper
• Genetic discoveries and advances in late‐onset Alzheimer’s disease

  2019cited by this paper
• Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms.

  2019cited by this paper
• Late-onset Alzheimer Disease

  2019cited by this paper
• P4-044: THERAPEUTIC POTENTIAL OF INNATE IMMUNITY STIMULATION BY CLASS B CPG ODN IN A TAUOPATHY MOUSE MODEL, RTG4510

  2019cited by this paper
• A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward.

  2019cited by this paper
• 2019 Alzheimer's disease facts and figures

  2019cited by this paper
• Opposing Roles of apolipoprotein E in aging and neurodegeneration

  2019cited by this paper
• The amyloid cascade and Alzheimer’s disease therapeutics: theory versus observation

  2019cited by this paper
• P1‐082: THERAPEUTICALLY EFFICACIOUS ANTI‐β‐SHEET MONOCLONAL DOES NOT INDUCE MICROHEMORRHAGES OR INFLAMMATION IN TGSWDI AD MICE WITH EXTENSIVE VASCULAR AMYLOID, INCREASING CHANCES OF SAFE TRANSLATABILITY

  2019cited by this paper
• Dissecting Alzheimer's Disease Molecular Substrates by Proteomics and Discovery of Novel Post-translational Modifications

  2019cited by this paper
• P3-054: ASSESSING THE EFFICACY AND SAFETY PROFILE OF CLASS C CPG ODN IN A NONHUMAN PRIMATE MODEL OF SPORADIC CAA

  2019cited by this paper
• Modulation of Innate Immunity by Amyloidogenic Peptides.

  2019cited by this paper
• Follow-up of active Aβ immunization in Alzheimer disease

  2019cited by this paper
• Large-scale proteomic analysis of human brain identifies proteins associated with cognitive trajectory in advanced age

  2019cited by this paper
• Defining and predicting transdiagnostic categories of neurodegenerative disease

  2019cited by this paper
• The spectrum of preclinical Alzheimer's disease pathology and its modulation by ApoE genotype.

  2018cited by this paper
• Quantitative proteomics of acutely-isolated mouse microglia identifies novel immune Alzheimer’s disease-related proteins

  2018cited by this paper
• Tau-targeting therapies for Alzheimer disease

  2018cited by this paper
• Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease

  2018cited by this paper
• Recent advances in the discovery and development of TLR ligands as novel therapeutics for chronic HBV and HIV infections

  2018cited by this paper
• Alzheimer's disease in Down syndrome: An overlooked population for prevention trials

  2018cited by this paper
• Untangling Genetic Risk for Alzheimer's Disease.

  2018cited by this paper
• Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease.

  2018cited by this paper
• Potential Novel Approaches to Understand the Pathogenesis and Treat Alzheimer’s Disease

  2018cited by this paper
• Genetics of Alzheimer's Disease

  2018cited by this paper
• Alzheimer's Disease-Associated β-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection.

  2018cited by this paper
• Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia.

  2018cited by this paper
• Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight

  2018cited by this paper
• Recent advancements toward therapeutic vaccines against Alzheimer’s disease

  2018cited by this paper
• Interactions of pathological proteins in neurodegenerative diseases

  2017cited by this paper
• Evolving Relevance of Neuroproteomics in Alzheimer's Disease.

  2017cited by this paper
• Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk

  2017cited by this paper
• Elucidating the Role of TREM2 in Alzheimer's Disease.

  2017cited by this paper
• Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease

  2017cited by this paper
• Targeting Apolipoprotein E/Amyloid β Binding by Peptoid CPO_Aβ17-21 P Ameliorates Alzheimer’s Disease Related Pathology and Cognitive Decline

  2017cited by this paper
• Alzheimer’s disease: experimental models and reality

  2017cited by this paper
• Dementia Research-A Roadmap for the Next Decade.

  2017cited by this paper
• CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies

  2017cited by this paper
• Late-Onset Alzheimer Disease.

  2017cited by this paper
• TREM2, Microglia, and Neurodegenerative Diseases.

  2017cited by this paper
• A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease.

  2017cited by this paper
• Alzheimer disease: Localized proteomics distinguishes AD subtypes

  2017cited by this paper
• High‐glucose induces tau hyperphosphorylation through activation of TLR9‐P38MAPK pathway

  2017cited by this paper
• Immunomodulation via Toll-like Receptor 9: An Adjunct Therapy Strategy against Alzheimer's Disease?

  2017cited by this paper
• Production of Monoclonal Antibodies to Pathologic β-sheet Oligomeric Conformers in Neurodegenerative Diseases

  2017cited by this paper
• The use of localized proteomics to identify the drivers of Alzheimer's disease pathogenesis

  2017cited by this paper
• Apolipoprotein E and Alzheimer’s disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins

  2017cited by this paper
• Innate Immunity Stimulation via Toll-Like Receptor 9 Ameliorates Vascular Amyloid Pathology in Tg-SwDI Mice with Associated Cognitive Benefits

  2017cited by this paper
• Targeting innate immunity for neurodegenerative disorders of the central nervous system

  2016cited by this paper
• Distinct prion-like strains of amyloid beta implicated in phenotypic diversity of Alzheimer's disease

  2016cited by this paper
• An Oral Aβ Vaccine Using a Recombinant Adeno-Associated Virus Vector in Aged Monkeys: Reduction in Plaque Amyloid and Increase in Aβ Oligomers

  2016cited by this paper
• Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

  2016cited by this paper
• Amyloid β-interacting partners in Alzheimer's disease: From accomplices to possible therapeutic targets.

  2016cited by this paper
• Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies

  2016cited by this paper
• Developing therapeutic vaccines against Alzheimer’s disease

  2016cited by this paper
• The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy

  2016cited by this paper
• Molecular genetics of early‐onset Alzheimer's disease revisited

  2016cited by this paper
• Microbes and Alzheimer's Disease.

  2016cited by this paper
• Immunosenescence of microglia and macrophages: impact on the ageing central nervous system.

  2016cited by this paper
• Alzheimer's disease

  2016cited by this paper
• Structural Variation in Amyloid-β Fibrils from Alzheimer’s Disease Clinical Subtypes

  2016cited by this paper
• P4‐018: Innate Immunity Stimulation Via Toll‐Like Receptor 9 as a Novel Therapeutic Approach in Alzheimer’s Disease

  2016cited by this paper
• The amyloid hypothesis of Alzheimer's disease at 25 years

  2016cited by this paper
• Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer’s Disease: Need for Prognostic Biomarkers?

  2016cited by this paper
• TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.

  2016cited by this paper
• Microglial toll-like receptors and Alzheimer's disease.

  2016cited by this paper
• Genetic variations underlying Alzheimer's disease: evidence from genome-wide association studies and beyond.

  2016cited by this paper
• P2‐324: The projected impact of the baby boomers on the trajectory of and spending on Alzheimer's disease

  2015cited by this paper
• Alzheimer's disease risk genes and mechanisms of disease pathogenesis.

  2015cited by this paper
• Rapidly progressive Alzheimer's disease features distinct structures of amyloid-β.

  2015cited by this paper
• Chemical cross-linking/mass spectrometry maps the amyloid β peptide binding region on both apolipoprotein E domains.

  2015cited by this paper
• Proteomic analysis of neurons microdissected from formalin-fixed, paraffin-embedded Alzheimer’s disease brain tissue

  2015cited by this paper
• Immunotherapeutic approaches for Alzheimer's disease.

  2015cited by this paper
• Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer’s Disease: What are the Roadblocks and How Can They Be Overcome?

  2015cited by this paper
• Multiple pathologies are common and related to dementia in the oldest-old

  2015cited by this paper
• Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

  2015cited by this paper
• Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

  2015cited by this paper
• Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

  2014cited by this paper
• Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.

  2014cited by this paper
• Immunotherapy for Alzheimer's disease.

  2014cited by this paper
• The Binding of Apolipoprotein E to Oligomers and Fibrils of Amyloid-β Alters the Kinetics of Amyloid Aggregation

  2014cited by this paper
• Genetic markers for diagnosis and pathogenesis of Alzheimer's disease.

  2014cited by this paper
• Amyloid β and Tau Alzheimer’s disease related pathology is reduced by Toll-like receptor 9 stimulation

  2014cited by this paper
• Blocking the apolipoprotein E/Amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology

  2014cited by this paper
• Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice

  2014cited by this paper
• Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases.

  2014cited by this paper
• Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

  2014cited by this paper
• Amyloid β and Tau Alzheimer’s disease related pathology is reduced by Toll-like receptor 9 stimulation

  2014cited by this paper
• Alzheimer's disease genetics: from the bench to the clinic.

  2014cited by this paper
• Genetics of Alzheimer’s Disease

  2014cited by this paper
• Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

  2013cited by this paper
• Immunotherapy for Alzheimer’s disease: hoops and hurdles

  2013cited by this paper
• Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer’s disease pathology in TgSwDI and 3xTg mouse models

  2013cited by this paper
• ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions

  2013cited by this paper
• Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer’s disease-related pathology

  2013cited by this paper
• Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide

  2012cited by this paper
• CpG Still Rocks! Update on an Accidental Drug

  2012cited by this paper
• Rapidly Progressive Alzheimer's Disease: A Multicenter Update

  2012cited by this paper
• The genetics of Alzheimer's disease.

  2012cited by this paper

• Coupling with poly (Cytosine)-Mediated signal amplification strategy and Aptamer-Antibody interaction for ultrasensitive detection of Aβ42

  2025cites this paper
• Plasma proteomics and lipidomics facilitate elucidation of the link between Alzheimer's disease development and vessel wall fragility

  2024cites this paper
• Alzheimer's disease progression detection based on optical fluence rate measurements using alternative laser wavelengths

  2024cites this paper
• Localized proteomic differences in the choroid plexus of Alzheimer's disease and epilepsy patients

  2023cites this paper
• Gait dysfunction in Alzheimer disease.

  2023cites this paper
• Comparison of serum neurodegenerative biomarkers among hospitalized COVID‐19 patients versus non‐COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia

  2022cites this paper
• An Essential Role for Alzheimer’s-Linked Amyloid Beta Oligomers in Neurodevelopment: Transient Expression of Multiple Proteoforms during Retina Histogenesis

  2022cites this paper
• Synthesis of Novel Pyrazolo[3,4-b]pyridines with Affinity for β-Amyloid Plaques

  2022cites this paper
• In Silico Analysis of the Antagonist Effect of Enoxaparin on the ApoE4–Amyloid-Beta (Aβ) Complex at Different pH Conditions

  2022cites this paper
• Amyloid-β targeting immunisation in aged non-human primate (Microcebus murinus)

  2022cites this paper
• Recent update on the heterogeneity of the Alzheimer’s disease spectrum

  2021cites this paper
• Passive Immunization With a Novel Monoclonal Anti-PrP Antibody TW1 in an Alzheimer’s Mouse Model With Tau Pathology

  2021cites this paper
• Imaging Techniques in Alzheimer’s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring

  2021cites this paper
• Olfactory Bulb Proteomics Reveals Widespread Proteostatic Disturbances in Mixed Dementia and Guides for Potential Serum Biomarkers to Discriminate Alzheimer Disease and Mixed Dementia Phenotypes

  2021cites this paper
• Elevation of Neurodegenerative Serum Biomarkers among Hospitalized COVID-19 Patients

  2021cites this paper
• APOE-amyloid interaction: Therapeutic targets

  2020cites this paper
• Alzheimer’s disease: many failed trials, so where do we go from here?

  2020cites this paper
• Understanding the Pathophysiology of Cerebral Amyloid Angiopathy

  2020cites this paper
• Class C CpG Oligodeoxynucleotide Immunomodulatory Response in Aged Squirrel Monkey (Saimiri Boliviensis Boliviensis)

  2020cites this paper
• Using Proteomics to Understand Alzheimer’s Disease Pathogenesis

  2019cites this paper